632 related articles for article (PubMed ID: 27637390)
1. Gene therapy for the CNS using AAVs: The impact of systemic delivery by AAV9.
Saraiva J; Nobre RJ; Pereira de Almeida L
J Control Release; 2016 Nov; 241():94-109. PubMed ID: 27637390
[TBL] [Abstract][Full Text] [Related]
2. Challenges in adeno-associated virus-based treatment of central nervous system diseases through systemic injection.
Huang L; Wan J; Wu Y; Tian Y; Yao Y; Yao S; Ji X; Wang S; Su Z; Xu H
Life Sci; 2021 Apr; 270():119142. PubMed ID: 33524419
[TBL] [Abstract][Full Text] [Related]
3. Gene therapy and neurodevelopmental disorders.
Gray SJ
Neuropharmacology; 2013 May; 68():136-42. PubMed ID: 22750077
[TBL] [Abstract][Full Text] [Related]
4. Widespread Central Nervous System Gene Transfer and Silencing After Systemic Delivery of Novel AAV-AS Vector.
Choudhury SR; Harris AF; Cabral DJ; Keeler AM; Sapp E; Ferreira JS; Gray-Edwards HL; Johnson JA; Johnson AK; Su Q; Stoica L; DiFiglia M; Aronin N; Martin DR; Gao G; Sena-Esteves M
Mol Ther; 2016 Apr; 24(4):726-35. PubMed ID: 26708003
[TBL] [Abstract][Full Text] [Related]
5. Sialic acid deposition impairs the utility of AAV9, but not peptide-modified AAVs for brain gene therapy in a mouse model of lysosomal storage disease.
Chen YH; Claflin K; Geoghegan JC; Davidson BL
Mol Ther; 2012 Jul; 20(7):1393-9. PubMed ID: 22588273
[TBL] [Abstract][Full Text] [Related]
6. Efficient CNS targeting in adult mice by intrathecal infusion of single-stranded AAV9-GFP for gene therapy of neurological disorders.
Bey K; Ciron C; Dubreil L; Deniaud J; Ledevin M; Cristini J; Blouin V; Aubourg P; Colle MA
Gene Ther; 2017 May; 24(5):325-332. PubMed ID: 28425480
[TBL] [Abstract][Full Text] [Related]
7. Retinal gene delivery by adeno-associated virus (AAV) vectors: Strategies and applications.
Schön C; Biel M; Michalakis S
Eur J Pharm Biopharm; 2015 Sep; 95(Pt B):343-52. PubMed ID: 25615882
[TBL] [Abstract][Full Text] [Related]
8. Delivery of an Adeno-Associated Virus Vector into Cerebrospinal Fluid Attenuates Central Nervous System Disease in Mucopolysaccharidosis Type II Mice.
Hinderer C; Katz N; Louboutin JP; Bell P; Yu H; Nayal M; Kozarsky K; O'Brien WT; Goode T; Wilson JM
Hum Gene Ther; 2016 Nov; 27(11):906-915. PubMed ID: 27510804
[TBL] [Abstract][Full Text] [Related]
9. AAV-PHP.B Administration Results in a Differential Pattern of CNS Biodistribution in Non-human Primates Compared with Mice.
Liguore WA; Domire JS; Button D; Wang Y; Dufour BD; Srinivasan S; McBride JL
Mol Ther; 2019 Nov; 27(11):2018-2037. PubMed ID: 31420242
[TBL] [Abstract][Full Text] [Related]
10. The advent of AAV9 expands applications for brain and spinal cord gene delivery.
Dayton RD; Wang DB; Klein RL
Expert Opin Biol Ther; 2012 Jun; 12(6):757-66. PubMed ID: 22519910
[TBL] [Abstract][Full Text] [Related]
11. Adeno-associated virus vectors and neurological gene therapy.
Ojala DS; Amara DP; Schaffer DV
Neuroscientist; 2015 Feb; 21(1):84-98. PubMed ID: 24557878
[TBL] [Abstract][Full Text] [Related]
12. Adeno-Associated Virus-Based Gene Therapy for CNS Diseases.
Hocquemiller M; Giersch L; Audrain M; Parker S; Cartier N
Hum Gene Ther; 2016 Jul; 27(7):478-96. PubMed ID: 27267688
[TBL] [Abstract][Full Text] [Related]
13. Adeno-Associated Virus Vector for Central Nervous System Gene Therapy.
Zhu D; Schieferecke AJ; Lopez PA; Schaffer DV
Trends Mol Med; 2021 Jun; 27(6):524-537. PubMed ID: 33895085
[TBL] [Abstract][Full Text] [Related]
14. A Safe and Reliable Technique for CNS Delivery of AAV Vectors in the Cisterna Magna.
Taghian T; Marosfoi MG; Puri AS; Cataltepe OI; King RM; Diffie EB; Maguire AS; Martin DR; Fernau D; Batista AR; Kuchel T; Christou C; Perumal R; Chandra S; Gamlin PD; Bertrand SG; Flotte TR; McKenna-Yasek D; Tai PWL; Aronin N; Gounis MJ; Sena-Esteves M; Gray-Edwards HL
Mol Ther; 2020 Feb; 28(2):411-421. PubMed ID: 31813800
[TBL] [Abstract][Full Text] [Related]
15. One episode of low intensity aerobic exercise prior to systemic AAV9 administration augments transgene delivery to the heart and skeletal muscle.
Pacak CA; Suzuki-Hatano S; Khadir F; Daugherty AL; Sriramvenugopal M; Gosiker BJ; Kang PB; Cade WT
J Transl Med; 2023 Oct; 21(1):748. PubMed ID: 37875924
[TBL] [Abstract][Full Text] [Related]
16. Adeno-Associated Virus (AAV) Vectors in the CNS.
McCown TJ
Curr Gene Ther; 2011 Jun; 11(3):181-8. PubMed ID: 21453285
[TBL] [Abstract][Full Text] [Related]
17. Intravenous Infusion of AAV for Widespread Gene Delivery to the Nervous System.
Gessler DJ; Tai PWL; Li J; Gao G
Methods Mol Biol; 2019; 1950():143-163. PubMed ID: 30783972
[TBL] [Abstract][Full Text] [Related]
18. Systemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pediatric disorders.
Bevan AK; Duque S; Foust KD; Morales PR; Braun L; Schmelzer L; Chan CM; McCrate M; Chicoine LG; Coley BD; Porensky PN; Kolb SJ; Mendell JR; Burghes AH; Kaspar BK
Mol Ther; 2011 Nov; 19(11):1971-80. PubMed ID: 21811247
[TBL] [Abstract][Full Text] [Related]
19. AAV vectors applied to the treatment of CNS disorders: Clinical status and challenges.
Kang L; Jin S; Wang J; Lv Z; Xin C; Tan C; Zhao M; Wang L; Liu J
J Control Release; 2023 Mar; 355():458-473. PubMed ID: 36736907
[TBL] [Abstract][Full Text] [Related]
20. Tyrosine Mutation in AAV9 Capsid Improves Gene Transfer to the Mouse Lung.
Martini SV; Silva AL; Ferreira D; Rabelo R; Ornellas FM; Gomes K; Rocco PR; Petrs-Silva H; Morales MM
Cell Physiol Biochem; 2016; 39(2):544-53. PubMed ID: 27384068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
